A new type of painkiller aimed at treating pain from an injury or surgery has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, also known by its brand name Journavx, ...

A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Wild weather has seen the Sydney Smash fizzle without a whimper as the Sydney Sixers shared the points with cross-town rivals the Sydney Thunder in a washout at the SCG. Watch every game of the ...

Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...

Vertex Pharmaceuticals' current market capitalization, exceeding $108 billion as of January 15, 2025, reflects strong investor confidence in its established cystic fibrosis (CF) franchise and its ...

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...